89 completed, 30 active not recruiting, 28 recruiting, 28 terminated. 200 Phase 3, 21 Phase 2.
Follow Nevi and Melanomas: new trials by email Literature Review of Nevi and Melanomas trials Research Report on Nevi and Melanomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma | Phase 3 | Not yet recruiting | Scancell Ltd | 550 | 2026-12-01 | 2026-09-11 |
| Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis Clinical decision support tool - Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 14000 | 2026-10-15 | 2026-10-22 |
| Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma: MagMen-II Superparamagnetic Iron Oxide, Technetium (99mTc) - Melanoma (Skin Cancer) | Phase 3 | Not yet recruiting | Vastra Gotaland Region | 254 | 2026-10-01 | 2026-09-03 |
| Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma Darovasertib, Crizotinib (Xalkori) - Uveal Melanoma | Phase 3 | Recruiting | IDEAYA Biosciences | 450 | 2026-09-01 | 2026-09-15 |
| Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma Adjuvant Therapy, Comprehensive Geriatric Assessment, Computed Tomography - Cutaneous Melanoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 428 | 2026-04-17 | 2026-09-24 |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma Darovasertib, Primary Local Therapy - Uveal Melanoma | Phase 3 | Recruiting | IDEAYA Biosciences | 520 | 2026-01-25 | 2026-05-06 |
| Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma MB11 (Proposed Nivolumab Biosimilar), EU-Opdivo®, US- sourced Opdivo® - Advanced (Unresectable or Metastatic) Melanoma | Phase 3 | Recruiting | mAbxience Research S.L. | 632 | 2025-12-29 | 2026-10-29 |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. Entrectinib - Haematological Malignancy, Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2025-11-30 | 2025-11-24 |
| NO Re-excision MelanomA - NORMA 2 Re-excision, No re-excision - Melanoma (Skin Cancer) | Phase 3 | Recruiting | Marieke Goodijk | 1749 | 2025-11-13 | 2026-04-15 |
| Contrast-enhanced Ultrasound for Sentinel Node Detection Sonazoid - Melanoma, Breast Cancer | Phase 2 / Phase 3 | Recruiting | The Netherlands Cancer Institute | 91 | 2025-09-18 | 2025-12-30 |
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide) - Melanoma (Skin Cancer), Melanoma Stage IIIB-IV | Phase 2 / Phase 3 | Recruiting | Linnaeus Therapeutics, Inc. | 135 | 2025-08-06 | 2026-04-22 |
| SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma Nivolumab, Nivolumab + Ipilimumab - Malignant Melanoma Stage III | Phase 3 | Recruiting | Hildur Helgadottir | 128 | 2025-07-10 | 2025-12-12 |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma IMA203, nivolumab plus relatlimab, lifileucel - Melanoma, Cutaneous Malignant, Mucosal Melanoma | Phase 3 | Recruiting | Immatics US, Inc. | 450 | 2025-01-14 | 2026-10-30 |
| Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy® JPB898 (Induction and Maintenance), Opdivo-EU (Induction), Opdivo-US (Induction) - Melanoma | Phase 3 | Terminated | Sandoz | 52 | 2024-12-19 | 2026-02-24 |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma RP2, Ipilimumab, Nivolumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Recruiting | Replimune, Inc. | 280 | 2024-12-17 | 2026-04-02 |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 3 | Active not recruiting | NRG Oncology | 274 | 2024-12-12 | 2026-09-14 |
| Adjuvant Tebentafusp in High Risk Ocular Melanoma Tebentafusp - Uveal Melanoma | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 290 | 2024-11-11 | 2026-06-30 |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) fianlimab, cemiplimab, relatlimab+nivolumab - Melanoma | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 560 | 2024-09-09 | 2026-10-26 |
| PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases PHP, IPI1/NIVO3, IPI3/NIVO1 - Uveal Melanoma, Liver Metastases | Phase 3 | Recruiting | Vastra Gotaland Region | 40 | 2024-06-10 | 2024-11-25 |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) Naporafenib, Dacarbazine, Temozolomide - Advanced or Metastatic NRAS-mutant Melanoma | Phase 3 | Active not recruiting | Erasca, Inc. | 78 | 2024-04-29 | 2026-02-27 |
Showing 20 of 200. Sign in to see all of them.
Melanoma (181) · Neoplasm Metastasis (23) · Uveal Melanoma (21) · Skin Neoplasms (17) · Neoplasms (16) · Breast Neoplasms (12) · Brain Neoplasms (6) · Carcinoma, Renal Cell (6) · Carcinoma, Non-Small-Cell Lung (5) · Colorectal Neoplasms (5) · Head and Neck Neoplasms (5) · Parkinson Disease 4, Autosomal Dominant Lewy Body (5) · Uterine Cervical Neoplasms (5) · Carcinoma, Hepatocellular (4) · Endometrial Neoplasms (4)
Neoplasms, Germ Cell and Embryonal (199) · Neoplasms, Nerve Tissue (199) · Neuroectodermal Tumors (199) · Neuroendocrine Tumors (199) · Neoplasms by Histologic Type (197) · Neoplasms by Site (196) · Neoplasms (184) · Skin and Connective Tissue Diseases (184) · Skin Diseases (182) · Skin Neoplasms (166) · Pathological Conditions, Signs and Symptoms (28) · Pathologic Processes (27) · Neoplastic Processes (24) · Eye Diseases (22)
Nivolumab (34) · Dacarbazine (29) · Ipilimumab (25) · pembrolizumab (23) · Interferon-alpha (10) · Interferon alpha-2 (9) · Temozolomide (9) · Vemurafenib (9) · Introns (8) · trametinib (8) · aldesleukin (7) · dabrafenib (7) · Chemotherapy, Adjuvant (6) · Cisplatin (5) · Interleukin-2 (5)
Bristol-Myers Squibb (19) · National Cancer Institute (NCI) (10) · Merck Sharp & Dohme LLC (9) · European Organisation for Research and Treatment of Cancer - EORTC (7) · Hoffmann-La Roche (6) · Biocad (5) · Novartis Pharmaceuticals (5) · GlaxoSmithKline (4) · Regeneron Pharmaceuticals (4) · Amgen (3) · Cancer Research UK (3) · Delcath Systems Inc. (3) · IDEAYA Biosciences (3) · Pfizer (3) · The Netherlands Cancer Institute (3)
United States (120) · United Kingdom (81) · France (78) · Italy (78) · Germany (76) · Canada (73) · Australia (72) · Spain (68) · Netherlands (61) · Belgium (52) · Poland (52) · Switzerland (50) · Israel (47) · Austria (40) · Sweden (40)
Alexander M. M. Eggermont, MD, PhD (3) · Lawrence E. Flaherty, MD (3) · Matthew Krebs, Dr (3) · Alberto S. Pappo, MD (2) · John M. Kirkwood, MD (2) · Michael B. Atkins, MD (2) · Agop Y. Bedikian, MD (1)
PMID 34225229, PMID 36653848, PMID 39504507, PMID 21600759, PMID 23054107, PMID 23504141, PMID 25649350, PMID 25667295, PMID 26446943, PMID 27864013, PMID 28662232, PMID 31166680, PMID 31395089, PMID 32746839, PMID 36648215, PMID 41811823, PMID 11745440, PMID 14665609, PMID 16198768, PMID 17005948, PMID 17159027, PMID 17337065, PMID 17620582, PMID 18620949, PMID 19001327, PMID 19118701, PMID 19349552, PMID 19430405, PMID 19433686, PMID 19621225, PMID 19793643, PMID 20385998, PMID 20525992, PMID 20614193, PMID 20956633, PMID 21087856, PMID 21256809, PMID 21546857, PMID 21631324, PMID 21639808, PMID 21639810, PMID 22027909, PMID 22202581, PMID 22256804, PMID 22480131, PMID 22575589, PMID 22648554, PMID 22663011, PMID 22694829, PMID 22975216
2023 (6), U10CA180820 (5), 2016 (4), 2018 (4), 2014 (3), 2015 (3), U10CA021115 (3), 2004 (2), 2008 (2), 2009 (2), U10CA180868 (2), U24CA196172 (2), 2005 (1), 2017 (1), P01CA012582 (1)